Can specific genetic variants change the risk of metabolic problems in MASLD?
Genetic variants play a role in how MASLD develops and progresses. Certain gene changes can make the liver more prone to fat buildup, inflammation, and scarring. For example, the PNPLA3-I148M variant is strongly linked to more severe liver disease 5. Other variants in the PON1 gene affect antioxidant activity and are tied to higher risk of dysglycemia (abnormal blood sugar) and liver fibrosis 3. These genetic factors can help identify people who may need closer monitoring or earlier treatment.
What the research says
A 2025 study found that the PNPLA3-I148M variant rewires lipid metabolism in human liver cells, increasing endoplasmic reticulum stress, mitochondrial dysfunction, and cell death via ferroptosis 5. This helps explain why carriers of this variant have a higher risk of progressing from steatosis to cirrhosis and end-stage liver disease 5. Another study identified two PON1 variants (rs2057681 and rs854572) that modulate PONase activity, an antioxidant enzyme; specific haplotypes were associated with increased risk of dysglycemia and liver fibrosis in a Portuguese cohort 3. Additionally, research on multiple risk variants (PNPLA3, TM6SF2, MBOAT7) showed that carrying three at-risk variants impairs mitochondrial bioenergetics in liver cells, and this defect can be detected in blood cells, suggesting a non-invasive way to identify high-risk patients 6. A separate study using patient-derived stem cells demonstrated that cells with MASLD risk variants accumulate more fat when exposed to oleate, and this functional test could predict MASLD risk with moderate accuracy 4. Together, these findings confirm that genetic variants directly influence metabolic dysfunction and liver damage in MASLD.
What to ask your doctor
- Should I consider genetic testing for PNPLA3, PON1, TM6SF2, or MBOAT7 variants to better understand my MASLD risk?
- If I carry high-risk variants, are there specific lifestyle changes or treatments that might help prevent progression?
- Could a blood test measuring mitochondrial function or PONase activity be useful for monitoring my liver health?
- How do these genetic risks interact with other factors like diet, exercise, or medications?
- Are there any clinical trials or emerging therapies targeting these genetic pathways that I might be eligible for?
This question is drawn from common patient questions about this topic and answered using cited medical research. We do not provide individualized advice.